Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotyktu in Moderate-to-Severe Plaque Psoriasis (POETYK-PSO-3)
NCT04167462Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of deucravacitinib in plaque psoriasis, sponsored by Bristol Myers Squibb. Started Nov 2019; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04167462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04167462.